MSML - ETF AI Analysis
Top Page
iShares MSCI USA Small-Cap ETF (MSML)
ISCBās rating suggests it is a solid but not top-tier small-cap ETF, with its quality driven by several strong, growing companies but tempered by some risks. Standout holdings like Okta and Zebra Technologies support the fund with strong financial performance, strategic growth initiatives, and positive momentum, while names like Guardant Health and Nutanix introduce more risk due to financial instability, leverage, and valuation concerns. The main risk factor is exposure to companies with profitability and valuation challenges, which can make the ETF more sensitive to market volatility.
MSML vs. SPDR S&P 500 ETF (SPY)
- AUM
- 272.24M
- Region
- North America
- Expense Ratio
- 0.04%
- Beta
- 0.98
- Issuer
- iShares
- Inception Date
- Jun 28, 2004
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- MSCI USA Small Cap
MSML Summary
The iShares Morningstar Small-Cap ETF (ISCB) is a fund that follows the Morningstar US Small Cap Extended Market Index, focusing on smaller U.S. companies with room to grow. It owns a wide mix of businesses across many sectors, including technology, health care, and financials. Well-known names in the fund include Roku and Best Buy. Someone might invest in ISCB to add diversification and growth potential to a portfolio by tapping into smaller, more agile companies. A key risk is that small-cap stocks can be more volatile, so the ETFās value can rise and fall more sharply than the overall market.
How much will it cost me?
The iShares Morningstar Small-Cap ETF (ISCB) has an expense ratio of 0.04%, which means youāll pay $0.40 per year for every $1,000 invested. This is lower than average because itās a passively managed fund that tracks an index, keeping costs down.
What would affect this ETF?
The iShares Morningstar Small-Cap ETF (ISCB) could benefit from economic growth and innovation in sectors like technology and healthcare, which make up a significant portion of its holdings. However, small-cap stocks are often more sensitive to interest rate hikes and economic slowdowns, which could negatively impact the ETF's performance. Additionally, its focus on U.S.-based companies means it may be affected by domestic regulatory changes or geopolitical events.
MSML Top 10 Holdings
ISCB is leaning into U.S. small-cap growth, with a clear tilt toward tech and innovation. Okta and Rubrik have been rising, helping power returns as investors warm to security and data-focused names. Dynatrace and Nutanix add more software firepower, though their mixed, sometimes cautious trading keeps the ride bumpy. On the health care side, Guardant Health and Revvity are climbing but still wrestling with profitability, which can cap their impact. Overall, the fund is driven by a cluster of smaller, fast-moving tech and health names rather than any single giant.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 MRNA | Moderna | 1.17% | $3.14M | $87.04B | 703.28% | 59Neutral |
 THC | Tenet Healthcare | 0.37% | $983.75K | $21.52B | 34.21% | 74Outperform |
 USFD | US Foods Holding | 0.36% | $960.06K | $22.06B | 36.04% | 74Outperform |
 VTRS | Viatris | 0.35% | $929.24K | $21.43B | 84.70% | 60Neutral |
 ROKU | Roku | 0.33% | $873.61K | $22.95B | 62.11% | 65Neutral |
 GH | Guardant Health | 0.31% | $831.86K | $21.28B | 135.07% | 61Neutral |
 WWD | Woodward | 0.31% | $836.97K | $19.40B | 33.00% | 79Outperform |
 RGLD | Royal Gold | 0.32% | $864.36K | $20.17B | 15.19% | 78Outperform |
 DINO | HF Sinclair Corporation | 0.31% | $820.65K | $22.27B | 147.46% | 68Neutral |
 RBRK | Rubrik, Inc. Class A | 0.28% | $757.64K | $23.30B | 42.94% | 50Neutral |
MSML Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MSML, the sentiment is Negative. The current price of 70.68 is below the 20-day moving average (MA) of 71.81, below the 50-day MA of 73.79, and below the 200-day MA of 70.78, indicating a bearish trend. The MACD of -0.67 indicates Negative momentum. The RSI at 38.81 is Neutral, neither overbought nor oversold. The STOCH value of 24.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MSML.
MSML Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| MSML | $70.68 | $79.00(11.77% Upside) | $272.24M | 0.04% | 66Neutral |
 SFLO | $38.75 | $47.91(23.64% Upside) | $843.36M | 0.49% | 68Neutral |
 OUSM | $47.57 | $54.55(14.67% Upside) | $800.17M | 0.48% | 72Outperform |
 BBSC | $83.18 | $110.82(33.22% Upside) | $725.53M | 0.09% | 63Neutral |
 EES | $64.94 | $80.26(23.60% Upside) | $682.56M | 0.38% | 67Neutral |
 JHSC | $45.98 | $57.56(25.19% Upside) | $678.67M | 0.42% | 68Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MSML | iShares MSCI USA Small-Cap ETF | 70.68 | 7.19 | 11.32% | |
| SFLO | VictoryShares Small Cap Free Cash Flow ETF | 38.75 | 10.18 | 35.66% | |
| OUSM | OShares U.S. Small-Cap Quality Dividend ETF | 47.57 | 3.81 | 8.70% | |
| BBSC | JPMorgan BetaBuilders U.S. Small Cap Equity ETF | 83.18 | 8.43 | 11.27% | |
| EES | WisdomTree U.S. SmallCap Fund | 64.94 | 10.21 | 18.65% | |
| JHSC | John Hancock Multifactor Small Cap ETF | 45.98 | 4.31 | 10.34% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.